Vaccinex stock: Melanoma study supports pepinemab immune strategy

Published on 10/31/2026 at 00:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vaccinex stock is tied to new pepinemab findings in melanoma. The pilot found immune remodeling, not proven clinical benefit.

What the melanoma findings mean

The study combined pepinemab with nivolumab and/or ipilimumab before surgery.
Its primary biomarker endpoint was met, while efficacy was outside the trial's design.
Larger randomized studies are needed to confirm the findings.

VCNX, US9186403013, Illustration mit AI erstellt.

Vaccinex announced on October 7, 2026, that a publication in Nature Communications reported findings from a pilot study of pepinemab in patients with metastatic melanoma. The announcement was carried by Yahoo Finance.

Biomarker signal meets study limits

The investigator-sponsored trial evaluated pepinemab with nivolumab and/or ipilimumab before surgery. Thirty-eight patients took part, and the predefined primary biomarker endpoint was met.

The findings linked pepinemab-containing treatment with changes in the tumor microenvironment, including signals associated with antigen presentation, immune-cell recruitment and organized immune structures. A greater abundance of mature lymphoid aggregates was associated with longer recurrence-free survival.

The study was biomarker-focused and was not designed to establish clinical efficacy. The reported association therefore supports further research but does not establish that pepinemab improves outcomes. Larger randomized studies will be needed to confirm the findings.

Vaccinex's development position

Vaccinex is a US clinical-stage biotechnology company focused on neurodegenerative disease and oncology. Its lead candidate, pepinemab, blocks semaphorin 4D and is being developed for Huntington's disease, Alzheimer's disease and cancer applications. The company also uses its ActivMAb platform to pursue pipeline expansion and strategic collaborations. Compared with diversified drugmakers such as Bristol Myers Squibb and Merck, Vaccinex is a smaller, specialized developer centered on an early-stage clinical pipeline.